Ghost Tree Capital, LLC Revance Therapeutics, Inc. Transaction History

Ghost Tree Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.34 - $4.73 $526,500 - $1.06 Million	-225,000 Reduced 50.0%	225,000 $578,000
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $348,750 - $698,250	75,000 Added 20.0%	450,000 $2.21 Million
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $145,250 - $280,000	25,000 Added 7.14%	375,000 $3.3 Million
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $2.01 Million - $4.39 Million	-175,000 Reduced 33.33%	350,000 $4.01 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $6.79 Million - $10.3 Million	275,000 Added 110.0%	525,000 $13.3 Million
Q1 2023 May 15, 2023	SELL	$18.36 - $35.27 $918,000 - $1.76 Million	-50,000 Reduced 16.67%	250,000 $8.05 Million
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $1.65 Million - $2.76 Million	-90,000 Reduced 23.08%	300,000 $5.54 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $5.59 Million - $11.1 Million	390,000 New	390,000 $10.5 Million

232

83.2M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.